2021 Indiana 100: Taltz leader sees more potential for blockbuster Lilly drug
Mathilde Merlet oversees one of Eli Lilly and Co.’s fastest-growing products, a medicine called Taltz that treats a variety of dermatology and rheumatology disorders.
Eli Lilly and Co.
Articles
Lilly’s COVID therapy hits wall as virus wanes
The use of COVID antibodies has fallen across the United States lately and, along with it, Lilly’s sales in that category.
Lilly’s stock gets big boost from competitor’s new Alzheimer’s treatment
Shares of Biogen competitors soared after aducanumab became the first drug cleared by the U.S. Food and Drug Administration to slow the course of the mind-wasting disease that afflicts 6 million Americans.
2021 Innovation Issue: Lilly’s disruptive model opens doors to women, minorities
For more than a century, Eli Lilly and Co. has pushed for innovation in the pharmaceutical industry. But six years ago, the drugmaker had to admit it was less than innovative in its own workforce.
Feds launch investigation of Lilly factory in New Jersey
Eli Lilly on Thursday said in a government filing that it has received a subpoena from the U.S. Justice Department for documents related to the factory and is cooperating with the investigation.
Lilly shares fall in pre-market trading after drugmaker’s profit dips
Shares of Eli Lilly and Co. dropped as much as 5% Tuesday morning after the Indianapolis-based drugmaker lowered guidance for full-year earnings.
Eli Lilly: Antibody combo works best on COVID-19 variants
The Indianapolis-based company is asking U.S. regulators to revoke their emergency authorization for the use of bamlanivimab alone, in favor of its combination with another drug.
Proposed Indiana voting law change faces corporate criticism
Stephen Fry, Eli Lilly and Co.’s senior vice president for human resources and diversity, told a legislative committee Tuesday that the company believed the bill aimed at reducing voter fraud wasn’t needed.
Lilly exec created hostile work environment for women, former lobbyist claims in suit
Sonya Elling filed suit Friday in federal court against the drugmaker, alleging that Leigh Ann Pusey, senior vice president for corporate affairs and communications, precluded her from engaging with members of Congress because she was “not a cute, young thing.”
FDA panel rejects Pfizer/Lilly arthritis drug tanezumab as too risky
The expert panel for the Food and Drug Administration voted 19-1 that the drug’s modest benefits don’t outweigh its considerable risks, even with proposed measures to restrict who gets the medicine.
Lilly’s Alzheimer’s drug shows modest benefit in mid-stage trial
Eli Lilly and Co. on Saturday morning presented highly anticipated details from a mid-stage study showing that its experimental drug slowed Alzheimer’s disease progression over about 18 months.
Insider alleges Lilly blocked her efforts to sound alarms about U.S. drug factory
Eli Lilly and Co. told Reuters news agency that it is working closely with the FDA to address concerns about the factory in Branchburg, New Jersey, which makes Trulicity.
Lilly signs deal to sell $210M worth of COVID-19 antibodies to U.S. government
The Indianapolis-based drugmaker said it will begin shipping the additional doses immediately to the federal government, which controls distribution of the drugs.
Indiana Senate panel advances bill that would pass along drug rebates to consumers
The bill pitted the two largest companies headquartered in Indianapolis—drugmaker Eli Lilly and Co. and health insurer Anthem Inc.—on opposite sides of the issue.
Lilly’s flush pipeline makes it Wall Street darling
If you follow the daily drumbeat of news emanating out of Lilly Corporate Center, you might not grasp how phenomenally well the company is poised to perform in the coming years.
Former Lilly CFO Smiley to lose millions of dollars under separation agreement
Josh Smiley, Lilly’s CFO since 2018, resigned from the company after the drugmaker said he had engaged in a improper personal relationship with an employee.
Lilly’s COVID-19 antibody combo gets U.S. emergency authorization
The combo treatment is the second COVID-19 antibody therapy from the Indianapolis-based drugmaker to gain an emergency authorization from the FDA.
Lilly CFO resigns after ‘inappropriate personal relationship’ with employee
Joshua Smiley, who was Lilly’s second-highest-paid employee, was named CFO in January 2018. Lilly said Smiley also engaged in “inappropriate personal communications” with other employees.
Hope at Lilly after years of Alzheimer’s failures
Lilly has spent three decades and more than $3 billion trying to find a way to treat Alzheimer’s disease. Its latest drug, donanemab, finally shows real promise.
Lilly quarterly profit surges, helped by new COVID-19 treatment
The antibody treatment bamlanivimab was Lilly’s second-highest selling product in the final quarter of 2020, trailing only the popular diabetes drug Trulicity.